Mateen Abbas

Dr. Mateen Abbas

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2025 in EXCLI Journal
Verified
Journal Article
Open access
MAMateen Abbas
Mateen Abbas
SSSyed Hassam Ali Sami
Syed Hassam Ali Sami
Márió GajdácsMárió Gajdács
Márió Gajdács
MTMuhammad Junaid Tariq
Muhammad Junaid Tariq
Malignant disorders continue to represent one of the major burdens of disease globally, especially in the context of premature deaths. Targeted anticancer treatments, including kinase inhibitors (KIs), have become crucial tools to disrupt the specific signaling pathways that are responsible for cancer growth following malignant transformation. Evidence demonstrates that KIs have substantially advanced precision oncology across multiple malignancies, with clinical success most notable in hematologic cancers and specific solid tumors, such as non-small cell lung cancer. Nonetheless, their long-term efficacy is often constrained by the emergence of acquired resistance, intratumoral heterogeneity, and off-target toxicities, underscoring the need for adaptive therapeutic strategies and combination regimens. While next-generation KIs and ongoing trials of KIs have the promise to expand the therapeutic landscape, the uneven distribution of clinical benefits across different cancer types reveals a considerable gap between molecular advances and real-world outcomes, leading to unequitable improvements in survival and quality of life for patients. Research also indicates disparities in access and affordability, raising concerns about their integration into routine care in low- and middle-income countries. The present review paper aims to provide a summary and a critical synthesis of the development, therapeutic potential, and clinical performance of novel of kinase inhibitors in oncology (i.e. zongeritinib, sunvozertinib, vimseltinib, mirdametinib, avutometinib and defactinib), authorized by the US Food and Drug Administration (FDA) in 2025, aiming to highlight both their transformative role and their inherent limitations. Taken together, KIs represent both a milestone and a challenge in oncology: they highlight the success of rational drug design and targeted therapy, yet show the need for continual innovation, improved global accessibility, and integration into multimodal strategies and standards of care to achieve durable survival benefits.

14 November 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
NNNadia Noreen
Nadia Noreen
AAAdeel Aslam
Adeel Aslam
MAMateen Abbas
Mateen Abbas
AMAsma Ghulam Mustafa
Asma Ghulam Mustafa
SJShazia Jamshed
Shazia Jamshed
NANaji Alqahtani
Naji Alqahtani
Background: The escalating burden of antimicrobial resistance (AMR) poses a critical threat to public health in Pakistan, with rates of high antibiotic consumption and limited standardized surveillance on AMR rates. Our study aimed to carry out a multicentric surveillance of AMR to generate regional antibiograms for Northern Punjab, Pakistan, to guide empirical antimicrobial therapy and stewardship efforts. Methods: A laboratory-based, retrospective cross-sectional study was conducted over a six-month period across three tertiary care hospitals. Socio-demographic, clinical, and microbiological data (including specimen type and antibiotic prescription rates) were collected from N = 485 patients with confirmed bacterial infections. Antimicrobial susceptibility testing was performed based on Clinical Laboratory Standards Institute (CLSI) recommendations. Statistical analyses were carried out using SPSS v.22.0. Results: In our study setting, Gram-positive bacteria were common causes (60.0%) of infections, with Staphylococcus aureus (12.2%) and Streptococcus pneumoniae (10.3%) being the most relevant. Among Gram-negative bacteria (40.0%), Escherichia coli (14.0%) and Pseudomonas aeruginosa (5.8%) were shown to be important pathogens. Overall, 25.0% of S. aureus isolates were methicillin-resistant (MRSA), while ~30% of E. coli showed resistance to third-generation cephalosporins (3GCs). Enterobacterales species had highly variable susceptibility rates (40–70%) for fluoroquinolones. Meropenem and vancomycin/linezolid retained high efficacy (>90%) against most Gram-negative and Gram-positive isolates, respectively. In all healthcare settings studied, ceftriaxone was the most frequently prescribed antibiotic. Conclusions: High levels of resistance against first-line antibiotics were noted in our setting of Northern Punjab, Pakistan, underscoring the critical need for robust antimicrobial stewardship programs, tailored to local institutional contexts, capabilities, and needs. The regional antibiogram developed based on our data may provide vital evidence for informing local empirical treatment guidelines, which need to be continuously updated.

1 September 2025 in Journal of Research in Pharmacy
Verified
Journal Article
Open access
PDF file
ASAttaullah Shah
Attaullah Shah
SAShawkat Ali
Shawkat Ali
HBHaroon Badshah
Haroon Badshah
MAMateen Abbas
Mateen Abbas
DNDurre Nayab
Durre Nayab
SSSyed Wadood Ali Shah
Syed Wadood Ali Shah
Drug-induced hepatotoxicity is a usual way that the liver can suffer harm regardless of the advantageous roles of liver. Gentamicin-induced hepatotoxicity is a significant clinical disadvantage. It is believed that gentamicin- induced hepatotoxicity is due to formation of free radicals. Like other synthetic antioxidant compounds, Schiff bases also have the ability to scavenge free radicals. This study emphasizes the hepatoprotective potential of Schiff bases (Designated as compound A and compound B) in a gentamicin-induced hepatotoxicity animal model. Thirty mices were randomly divided into six groups of five each. Group 1 was injected with 0.9% normal saline intraperitoneally (I.P.) per day and served as control while group 2 received gentamicin I.P. at a dose level of 100mg/kg/day. Group 3 received gentamicin 100mg/kg/day I.P. and compound SW8/SB at a dose level of 25mg/kg/day orally. Group 4 was injected with gentamicin 100mg/kg/day I.P. and SW8/SB at a dose level of 50mg/kg/day orally. Similarly group 5 received gentamicin 100mg/kg/day I.P. and SW10/SB at a dose level of 25mg/kg/day orally. Group 6 received 100mg/kg/day of gentamicin I.P. and 50mg/kg/day of SW10/SB orally. The said procedure lasted for eight days. Then liver function was evaluated by measurement of biomarkers of the liver, including total bilirubin, alkaline phosphatase, and alanine aminotransferase. İn addition to this, histological studies were performed to point out pathological changes in liver. Gentamicin administration elevated serum level of alanine aminotransferase, alkaline phosphatase and total bilirubin as well as gentamicin treatment also caused histopathological alterations. However, administration of Schiff bases reduced both serum level of hepatic biomarkers and histopathological changes. The 50mg/kg of compound SW10/SB showed almost normal histoarchitecture. It is concluded that Schiff bases have the ability to reduce gentamicin-induced hepatotoxicity in mice. However, further studies are still required to further determine the safety and physiological mechanisms behind this effect.

29 July 2021 in Ageing International
Verified
Journal Article
Closed access
PDF file
MAMateen Abbas
Mateen Abbas
SJSadaf Jabeen
Sadaf Jabeen
AIAqsa Idrees
Aqsa Idrees
MSMalik Saad Safdar
Malik Saad Safdar
ASAsif Safdar
Asif Safdar
MSMuhammad Rafeel Sherazi
Muhammad Rafeel Sherazi

21 December 2021 in Research Square
Verified
Preprint
Open access
PDF file
UMUrmah Mahrosh
Urmah Mahrosh
AKAyesha Baber Kawaish
Ayesha Baber Kawaish
MAMateen Abbas
Mateen Abbas
Background The healthcare system in Pakistan is facing a shortage of human resources and appropriate and sustainable financial measures and therefore fails to provide optimum services to the population of Pakistan. Furthermore, research is limited in the healthcare institutes; therefore, there is a scarcity of information about patient satisfaction with pharmacists and pharmacy services in Pakistan. As evident from the inadequate information in the literature, patients’ opinions about the pharmacy services in Pakistan are important [1]. Therefore, the current study was designed to assess patient satisfaction with the pharmacy performance of the outpatient pharmacy and its variation with socio-demographic characteristics in twin cities of Pakistan (Rawalpindi and Islamabad). Method A cross-sectional study design was used to assess the patient satisfaction through convenience sampling technique. Minimum sample size of 250 respondents who visit pharmacy department of public and private hospital for pharmaceutical care were included in this study. A pre validated tool was used to assess the patient satisfaction. Data was clean coded and import into spss for analysis. Descriptive and inferential statistic was applied to calculate frequency, standard deviation, mean deviation and p value to find the association among different domain of patient satisfaction with different demographic characteristics of respondents. Result Current study shows overall patients were satisfied from pharmacy services provided by government and private hospitals. Furthermore patient satisfaction towards pharmacist medication advice was very good however patient satisfaction towards pharmacist approach was good while patient perception with pharmacy setting, drug availability and cost were underrated. Significance difference (p ≤ 0.05) was observed in pharmacist’s approach with different gender, age groups and qualification. No significant difference (p ≥ 0.05) was observed in pharmacy setting drug availability and cost with different gender, age groups and marital status of respondents. However Significance difference (p ≤ 0.05) was observed in pharmacy setting drug availability and cost with different level of education patients with less education had better satisfaction as compared to highly educated respondents. Furthermore Significance difference (p ≤ 0.05) was observed in pharmacy setting drug availability and cost with occupation. Self-employee and government employee had low satisfaction score while other had better satisfactory score. Significance difference (p ≤ 0.05) was observed in pharmacist’s approach with different gender, age groups and qualification. Females had better satisfactory score as compared to female. Younger age group had better satisfaction as compared to elderly. Patients belong to higher educational groups had better satisfaction toward pharmacist approach as compared to low qualification groups respondents. Furthermore No significant difference (p ≥ 0.05) was observed in pharmacist’s approach with marital status and number of visits Conclusion Current study concluded that overall patient had average satisfaction score. Patients shows a better satisfaction towards pharmacist behavior/ way of handling the patients, information provided by pharmacist regarding medicine. Patient had less satisfaction towards the location of pharmacy, Availability and affordability of medicine. Patient shows negative satisfaction regarding waiting area and counselling area at in door patient pharmacy. It has been observed that educated respondents shows high level of satisfaction towards pharmacist availability and information provided by the pharmacist.

27 January 2026 in Epidemiologia
Verified
Journal Article
Open access
PDF file
MAMateen Abbas
Mateen Abbas
Márió GajdácsMárió Gajdács
Márió Gajdács
GBGeorgina Balogh
Georgina Balogh
SASana Ahmed
Sana Ahmed
RMRabia Mahfooz
Rabia Mahfooz
AKAbad Khan
Abad Khan
Background/Objectives: Prostate cancer (PC) is one of the most commonly diagnosed malignancies globally; depending on the treatment strategy used, erectile dysfunction (ED) is a frequently reported adverse outcome among PC patients. The current study evaluated ED prevalence among Pakistani PC patients and its effects on physical, psychological, and social well-being, aiming to address critical gaps in survivorship care for this population. Methods: A cross-sectional, multicenter, observational, questionnaire-based study was conducted in Rawalpindi and Islamabad, Pakistan, from February to April 2025. Health-related quality of life (HRQoL) among PC patients was measured using the Short Form Health Survey 36 (SF-36), while ED prevalence and severity were assessed by the International Index of Erectile Function (IIEF) instrument. Results: Among N = 400 PC patients, surgical treatments predominated (radical prostatectomy: 61.0%; n = 244), while hormonal (androgen-deprivation therapy: 31.5%; n = 126) and chemotherapy (23.3%; n = 93) were also commonly utilized. ED experience was high among PC patients in the erectile function (40.8%; n = 163) and in the intercourse satisfaction (45.0%; n = 180) domains; these showed moderately strong and significant positive correlations across all SF-36 domains, particularly physical functioning (r = 0.52; p < 0.001) and social functioning (r = 0.49; p < 0.001). Regression analysis confirmed sexual function domains explained 60% of HRQoL variance (adjusted R2 = 0.60). Conclusions: This study reveals high rates of treatment-related ED—and its biopsychosocial impact–among Pakistani PC patients, with significant negative impacts on HRQoL. The findings underscore the urgent need to integrate sexual health management into standard oncological care practices to improve holistic patient outcomes.